Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
2seventy bio, Inc. - Common Stock
(NQ:
TSVT
)
3.850
+0.090 (+2.39%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about 2seventy bio, Inc. - Common Stock
< Previous
1
2
3
Next >
2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023
May 11, 2023
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
May 03, 2023
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Present New Preclinical and Clinical Data from Broad Portfolio of Investigational Cell Therapies at the ASGCT 26th Annual Meeting
May 02, 2023
From
2seventy bio
Via
Business Wire
2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program
May 01, 2023
From
2seventy bio
Via
Business Wire
2seventy bio to Report First Quarter 2023 Financial Results on May 3, 2023
April 28, 2023
From
2seventy bio, Inc.
Via
Business Wire
Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma
April 17, 2023
From
Bristol Myers Squibb
Via
Business Wire
2seventy bio Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Progress
March 16, 2023
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Announces Appointment of Wei Lin, M.D. to Board of Directors
March 08, 2023
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Participate in 43rd Annual TD Cowen Health Care Conference
March 03, 2023
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Announces Pricing of Upsized Public Offering of Common Stock
February 28, 2023
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Announces Proposed Public Offering of Common Stock
February 28, 2023
From
2seventy bio, Inc.
Via
Business Wire
Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Results from Phase 3 KarMMa-3 Study
February 10, 2023
From
Bristol Myers Squibb
Via
Business Wire
2seventy bio to Participate in Upcoming Investor Conferences
February 01, 2023
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Provides Company Outlook for 2023
January 09, 2023
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Announces Expanded Translational Collaboration with Regeneron to Develop New Cell Therapy-Based Combinations for Solid Tumors
January 06, 2023
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
November 07, 2022
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Present Data from KarMMa-2 Study of Abecma (idecabtagene vicleucel) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
November 03, 2022
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies
October 27, 2022
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Announces Plans to Initiate KarMMa-9 Study of Abecma (idecabtagene vicleucel) in Newly Diagnosed Multiple Myeloma Patients
September 07, 2022
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Participate in Upcoming Investor Conferences
August 31, 2022
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
August 10, 2022
From
2seventy bio, Inc.
Via
Business Wire
Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma
August 10, 2022
From
Bristol Myers Squibb
Via
Business Wire
2seventy bio to Participate in Upcoming Investor Conferences
August 03, 2022
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
June 06, 2022
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
May 12, 2022
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Presents New Preclinical Data on bbT369, an Investigational Dual-Targeting Gene-Edited CAR T Cell Therapy, at the AACR Annual Meeting
April 08, 2022
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Participate in CG Horizons in Oncology Virtual Conference
April 07, 2022
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress
March 22, 2022
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Secures $170 Million in Private Placement Equity Financing
March 16, 2022
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Announces Key Management Appointments
February 14, 2022
From
2seventy bio, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.